SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Maximize Therapy Impact

Gallant™ ICD and CRT-D Devices

ABOUT

GALLANT™ CRT-D
GALLANT™ ICD

Gallant ICDs and CRT-Ds

Available in DF-4 and DF-1 configurations to improve quality of life for patients at every stage of therapy.

Abbott Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are built with exclusive algorithms proven to deliver better patient outcomes that have the potential to save more lives. It is this type of innovation that drives us at Abbott to personalize therapy and restore quality of life for patients. 

Options to Achieve the Narrowest QRS for Improved Response.1

 

 

SyncAV™ CRT technology provides the most QRS narrowing options at implant for patients. QRS narrowing after CRT implantation allows improved mortality. In patients with LBBB, QRS narrowing after CRT implant is associated with 2x lower mortality.2

24% narrower QRS
gradient background
gradient background

Potential to Save More Lives with Therapy Assurance.

VF Therapy Assurance is the only technology to provide an additional safety net for difficult-to-detect ventricular arrhythmias. Without VF Therapy Assurance, ventricular tachyarrhythmias with low and varying signal amplitudes may not be successfully identified.3,4

of patients who received HV therapy due to VF Therapy Assurance's enhanced detection would have been otherwise untreated for potentially life-threatening arrhythmias.3 

86% of patients

Protect Patients with a Physiologic Waveform. No DFT Test Needed.

 

 

DeFT Response™ technology is the industry’s most flexible option for the management of high defibrillation thresholds. The algorithm supports a 10J shock safety margin for patients.5

24% narrower QRS
gradient background
gradient background

Real-World Clinical Evidence

41% reduction in heart
failure readmissions6

41%

34% reduction in all-cause
hospitalization readmissions6

34%

23% reduction ($1,135)
in 2-year cost6

23%

 

$4,031

lifetime savings per
CRT patient6

 

Why Do We Implant Defibrillators?
Because every patient deserves life-saving therapy.

Abbott’s ICD and CRT-D platforms are designed with a focus on providing the best outcome for the patient. See the story of Rob, a United States Navy veteran, who experienced cardiac arrest while in the best shape of his life.

His heart had to be shocked five times on the way to the hospital, and doctors did not believe he would make it. After being implanted with a Gallant ICD, Rob and his family feel confident that he is now receiving the therapy he needs to stay alive.

References

  1. Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. http://jaha. ahajournals.org/content/ 7/3/e007489. Accessed June 29, 2018.
  2. Jastrzebski M, Baranchuk A, Fijorek K, et al. Cardiac resynchronization therapy-induced acute shortening of QRS duration predicts long-term mortality only in patients with left bundle branch block. Europace. 2019 Feb 1;21(2):281-289. doi: 10.1093/europace/euy254. PMID: 30403774.
  3. Wilkoff BL, Sterns LD, Katcher MS, et al. Novel Ventricular Tachyarrhythmia Detection Enhancement Detects Undertreated Life- Threatening Arrhythmias. Heart Rhythm 02. 2021 Nov 18;3(1):70-78. doi: 10.1016/j.hroo.2021.11.0092 021.
  4. Stroobandt RX, Duytschaever MF, Strisciuglio T, et al Failure to detect life-threatening arrhythmias in ICDs using single-chamber detection criteria. Pacing Clin Electrophysiology. 2019;42:583-594. DOI:10.1111/pace.13610.3
  5. Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71-75.
  6. Varma N, Hu Y, Connolly AT, Thibault B, Singh B, Mont L, Nabutovsky Y, Zareba W. Gain in real-world cardiac resynchronization therapy efficacy with SyncAV dynamic optimization: Heart failure hospitalizations and costs. Heart Rhythm. 2021 Sep;18(9):1577-1585.  doi: 10.1016/j.hrthm.2021.05.006. Epub 2021 May 7. PMID: 33965608.

MAT-2412058 v1.0 | item only approved for EMEA use

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0